Opioids

Back pain
#Chronic pain #Drug abuse #FDA #Opioids #Painkillers #Protega

FDA approves abuse-deterrent immediate-release 10mg opioid

The US Food and Drug Administration (FDA) has approved Roxybond (oxycodone hydrochloride) 10mg for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The approval makes Roxybond the first FDA-approved abuse-deterrent immediate release (IR) 10mg oxycodone formulation… Read More

#News #Regulatory

#Chronic pain #Grünenthal #Mergers and acquisitions #Opioids #Valinor Pharma

Grünenthal acquires Valinor Pharma for $250m

German company Grünenthal has acquired US-based Valinor Pharma along with its product Movantik (naloxegol) for approximately $250 million. Movantik is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Gross sales from the drug in the United States (US)… Read More

#Business & Investment #News

#Addiction #Antibodies #Cessation Therapeutics #Drug abuse #Monoclonal antibodies #Opioids #Overdose

Can an antibody therapy prevent fentanyl overdoses?

DDW Editor Reece Armstrong speaks to Tracy M Woody, President and Chief Executive Officer of Cessation Therapeutics, about the company’s goal to develop an antibody therapy to prevent fentanyl overdoses. Cessation Therapeutics is a pharmaceutical company that is developing antibody therapies to prevent and reverse overdosing… Read More

#Exclusive Content

Pain killers
#Drug development #Ensysce Biosciences #Opioids #Painkillers #Public health

In Conversation With: Dr Lynn Kirkpatrick, Ensysce Biosciences

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr Lynn Kirkpatrick, CEO… Read More

#News